Abstract
Objective: The aim of this study was to understand the preferences of U.S. oncologists and patients for poly(ADP-ribose) polymerase inhibitors (PARPi's) as second-line maintenance therapy for epithelial ovarian cancer, including tradeoffs they are willing to make between efficacy and toxicity risks.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
